Neuroendocrine Carcinoma — Trials

Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 514
Recruiting: 261
Ph III recruiting: 29
Growth YoY: +4.2%
Industry share: 38%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (213)

clinicaltrialsPublishedShowing 451–454 of 454 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00397293	Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer	completed	Phase 1 / Phase 2	36	Ascenta TherapeuticsINDUSTRY	3	Aug 24, 2010	clinicaltrials
NCT00423254	Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.	completed	Phase 1	12	Mannkind CorporationINDUSTRY	1	Aug 3, 2010	clinicaltrials